EnergyCentral.com, an Internet publisher for the electric power and energy industry, just published an article by Shlomi Palas, CEO of Bluesphere Corporation. Bluesphere, ticker BLSP, is an energy company that develops, manages and owns clean tech waste-to-energy projects.

The article is titled, “Post State of the Union Address – Waste-to-Energy addresses all of the President’s Issues on Environment”. In the article, Palas points out that clean-energy advocates have increasingly called on the president to ditch his agnostic “all of the above” approach to energy policy and embrace what they say is a “best-of-the-above” energy policy.

One technology in the “best-of-the-above” category riding a huge wave that is sweeping the US is Waste-to-Energy. Waste-to-Energy converts waste that would normally go into landfills into clean energy. It is in its very early stages of adoption in the U.S. There is demand for Waste-to-Energy from municipalities and some of the largest companies are investing in the segment.

Bluesphere is about to break ground on its first Waste-to-Energy facility in the U.S.. The facility is backed by $17.8 million in project financing from Caterpillar and over $6 million from a clean-tech fund. Major electric utility companies Duke Energy and National Grid have signed long term power purchase agreement with Bluesphere. Waste-to-Energy technology tackles and solves three major issues which are mentioned in Obama’s speech:
– Waste-to-Energy reduces carbon pollution
– It reduces the amount of waste going into landfills
– And it contributes to Obama’s target to reduce the use of fossil oil as we generate green electricity

As a result of the President’s focus and supporting budgets, the U.S. is beginning to see a tectonic movement in a global multi-billion industry and Waste-to-Energy is at the forefront of it.

To read the entire article please visit: http://www.energycentral.com/generationstorage/environmentalemissionsandcarbonmanagement/articles/2876/Post-State-of-the-Union-Address-Waste-to-Energy-addresses-all-of-the-President-s-Issues-on-Environment

JERUSALEM, April 10, 2014 /PRNewswire/ — Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Intellectual Property Department of Hong Kong has granted the Company’s patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins.”

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD™) technology is based on over 30 years of research by top research scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently in Phase 2 clinical trials on patients with type 1 diabetes (T1DM) and type 2 diabetes (T2DM) under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral GLP-1 analog capsule (ORMD-0901). The company’s corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release, please visit www.oramed.com

Pompano Beach, Fla., April 10, 2014 (GLOBE NEWSWIRE) — DS Healthcare Group, Inc. (NASDAQ:DSKX), a leading developer of personal care products, today announced it has signed a distribution agreement with Drogaria Iguatemi, the leading high-end retail drug store chain in Sao Paulo, Brazil. This marks the second major distribution agreement signed by DS Healthcare in Brazil’s $43 billion beauty industry. The Company’s products are experiencing robust sales growth in the Rio de Janeiro metropolitan area, as well as through DS Healthcare’s Brazilian e-commerce site.

The Sao Paulo metropolitan area has a population of 20 million, in one of the fastest growing beauty markets in the world. According to a U.S. Department of Commerce report titled, Doing Business in Brazil, “Hair care products make up the largest segment of the Brazilian cosmetics and toiletries market. Shampoo sales, both imported and locally made, constitute about 50 percent of domestic sales; they are divided evenly between Brazilian and well-known multinational suppliers.”

Drogaria Iguatemi has Sao Paulo’s most affluent chain of pharmacies. Selecting to carry only the most important brands in medicine, cosmetics, derma-cosmetics and skin care products in the world. Drogaria Igautemi has already begun retailing DS Healthcare’s products.

Director of Drogaria Iguatemi, Leonardo Diniz commented, “DS Healthcare’s product line, and specifically its hair care products are a fantastic fit for our chain. Brazilians love their hair and attach much more importance to hair health and appearance than people of other cultures. This is evidenced in the high degree of spending per capita for hair care and beauty in Brazil. We are very excited to get these products on our shelves.”

“Brazil is one of the largest markets in the world for our products. Our in-country roll out strategy there is on schedule and we are pleased with the results so far. As the leading high-end pharmacy and beauty products chain in Sao Paulo, Drogaria Iguatemi offers us an ideal retail distribution channel to launch our product lines into this very important metropolitan beauty market,” added DS Healthcare President and CEO Daniel Khesin.

According to Euromonitor, a market research firm, the Brazilian beauty industry generated $43 billion in sales in 2011, an increase of 142% over the last five years, putting it in position to overtake Japan as the world’s second-largest beauty market within several years.